Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant financial losses for investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Inspire securities between August 6, 2024, and August 4, 2025 [1]. - Allegations include that the company failed to disclose poor demand for its product and had surplus inventory, which affected the transition to the new treatment [1]. - The lawsuit claims that Inspire Medical did not complete essential tasks for a successful product launch, contrary to their public assurances [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers [2]. - The company admitted that software updates necessary for billing were not effective until July 1, leading many centers to continue using an earlier version of the product [2]. - Following the announcement, Inspire's stock price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 per share [2].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met once inventory was available [5]. - Contrary to these assurances, Inspire failed to adequately prepare clinicians and payors, leading to delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which concealed significant operational failures that ultimately led to a drastic cut in guidance and a stock price crash [3][5]. - Key undisclosed operational issues include: - Medicare claims software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device impacted demand for the new Inspire V, leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026, to discuss their legal rights [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has faced significant setbacks and resulted in a substantial drop in stock price [2][4][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Inspire Medical to contact them to discuss their legal options [1]. - The firm is reminding investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. Group 2: Company Performance and Issues - Inspire Medical announced on August 4, 2025, that the launch of its Inspire V device faced significant delays due to treatment centers not completing necessary training and onboarding [5]. - The company also reported billing and reimbursement challenges, stating that while Medicare approved a CPT code for Inspire V, software updates for claims processing were not effective until July 1, 2025, leading to continued use of the older Inspire IV system [5]. - Inspire Medical's launch of Inspire V has been affected by weak demand and excess inventory, resulting in a more than 80% cut in its 2025 earnings guidance [6]. - Following these issues, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 to $87.91, erasing approximately $1.2 billion in market capitalization [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Inspire Medical Systems, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its focus on innovative solutions for obstructive sleep apnea [1][2]. Company Overview - Inspire Medical Systems specializes in developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea [3]. - The company's proprietary Inspire therapy is recognized as the first and only neurostimulation technology approved by the FDA, EU MDR, and PDMA for treating moderate to severe obstructive sleep apnea [3]. Presentation Details - The presentation is scheduled for 12:45 p.m. Eastern Time and will be available via a live webcast [2]. - A replay of the presentation will be accessible for two weeks in the Event Archive section of Inspire's Investor website [2]. Contact Information - Investor relations can be reached through Ezgi Yagci, Vice President, at ezgiyagci@inspiresleep.com or by phone at 617-549-2443 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 5, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Specifics - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to misleading statements that caused investor losses when the truth was revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met once inventory was available [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].